Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lintuzumab-Ac-225 + Venetoclax + ASTX-727 in Newly Diagnosed AML
NCT06802523Phase 1Suspended
- Sponsor
- National Cancer Institute
- Start
- Nov 2026
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lintuzumab satetraxetan ac-225 in acute myeloid leukemia (AML) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Incidence of dose limiting toxicities up to 42 days and Overall response rate up to 5 years. Started Nov 2026; status: suspended.
02
Drugs
lintuzumab satetraxetan ac-225
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06802523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06802523.